Skip to content

Erasca, Inc. ERAS Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
$537K+5,867%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$578K
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s payments of stock issuance costs?
Erasca, Inc. (ERAS) reported payments of stock issuance costs of $16.04M in Q1 2026.